Derik De Bruin
Stock Analyst at B of A Securities
(4.53)
# 294
Out of 4,761 analysts
207
Total ratings
65.49%
Success rate
14.5%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $11.51 | +39.07% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $377.50 | +8.61% | 13 | Feb 13, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $113.81 | +21.26% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $535.81 | +23.18% | 18 | Dec 13, 2024 | |
| MYGN Myriad Genetics | Maintains: Underperform | $15 → $13 | $14.65 | -11.23% | 12 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $192.90 | +21.83% | 3 | Dec 13, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $75 → $72 | $50.18 | +43.48% | 6 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $162.49 | +29.24% | 5 | Dec 13, 2024 | |
| A Agilent Technologies | Maintains: Neutral | $153 → $150 | $135.90 | +10.38% | 31 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $210.72 | +68.47% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $20.95 | +24.11% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $248.65 | +8.99% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $171.80 | +5.94% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $51.55 | +55.19% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $212.02 | +36.78% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $22.53 | -33.42% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $15.23 | +37.93% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $11.21 | +123.02% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $23.05 | +38.86% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $96.15 | +4.00% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $64.61 | +33.11% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.44 | +192.79% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,292.53 | +17.99% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.30 | +183.22% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $204.14 | +27.36% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $11.66 | +929.16% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $39.09 | +60.12% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $159.24 | -24.64% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $4.29 | +110.04% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $455.48 | -48.41% | 3 | Nov 2, 2018 |
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $11.51
Upside: +39.07%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $377.50
Upside: +8.61%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $113.81
Upside: +21.26%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $535.81
Upside: +23.18%
Myriad Genetics
Dec 13, 2024
Maintains: Underperform
Price Target: $15 → $13
Current: $14.65
Upside: -11.23%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $192.90
Upside: +21.83%
Exact Sciences
Dec 13, 2024
Maintains: Buy
Price Target: $75 → $72
Current: $50.18
Upside: +43.48%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $162.49
Upside: +29.24%
Agilent Technologies
Dec 13, 2024
Maintains: Neutral
Price Target: $153 → $150
Current: $135.90
Upside: +10.38%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $210.72
Upside: +68.47%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $20.95
Upside: +24.11%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $248.65
Upside: +8.99%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $171.80
Upside: +5.94%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $51.55
Upside: +55.19%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $212.02
Upside: +36.78%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $22.53
Upside: -33.42%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $15.23
Upside: +37.93%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $11.21
Upside: +123.02%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $23.05
Upside: +38.86%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $96.15
Upside: +4.00%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $64.61
Upside: +33.11%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.44
Upside: +192.79%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,292.53
Upside: +17.99%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.30
Upside: +183.22%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $204.14
Upside: +27.36%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $11.66
Upside: +929.16%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $39.09
Upside: +60.12%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $159.24
Upside: -24.64%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $4.29
Upside: +110.04%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $455.48
Upside: -48.41%